Natco Pharma surges on launching first generic version of Nexavar Tablets in US market
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Natco Pharma is currently trading at Rs. 713.95, up by 21.90 points or 3.16% from its previous closing of Rs. 692.05 on the BSE.
The scrip opened at Rs. 699.80 and has touched a high and low of Rs. 729.95 and Rs. 686.05 respectively. So far 12738 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1188.05 on 06-Jul-2021 and a 52 week low of Rs. 607.95 on 31-May-2022.
Last one week high and low of the scrip stood at Rs. 729.95 and Rs. 607.95 respectively. The current market cap of the company is Rs. 13235.39 crore.
The promoters holding in the company stood at 48.81%, while Institutions and Non-Institutions held 28.09% and 23.10% respectively.
Natco Pharma has launched the first generic version of Nexavar (Sorafenib) Tablets in 200 mg strength today in the U.S. market. The product will be launched by Natco's commercial partner Viatris, a global pharmaceutical company.
Sorafenib is prescribed for treatment of unresectable Hepatocellular Carcinoma (HCC), advanced Renal Cell Carcinoma (RCC) and Differentiated Thyroid Carcinoma (DTC). Nexavar registered sales of $69.7 million for the year ending December 2021 as per industry sales data.
Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.
